BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36591468)

  • 1. m
    Yuan B; Qin H; Zhang J; Zhang M; Yang Y; Teng X; Yu H; Huang W; Wang Y
    Front Oncol; 2022; 12():1087753. PubMed ID: 36591468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
    Liu X; Ma C; Liu H; Sun Z; Luo J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer.
    Zhu J; Jiang Y; Wang T; Wu A; Zhou T; Zhang A; Tang Y; Shen Z; Wang J; Zhou H; Shi J; Chen J
    Dis Markers; 2022; 2022():2989200. PubMed ID: 35186164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-omics analysis of m
    Wu X; Bai Z
    Sci Rep; 2021 Oct; 11(1):20921. PubMed ID: 34686691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-Talk of Multiple Types of RNA Modification Regulators Uncovers the Tumor Microenvironment and Immune Infiltrates in Soft Tissue Sarcoma.
    Qi L; Zhang W; Ren X; Xu R; Yang Z; Chen R; Tu C; Li Z
    Front Immunol; 2022; 13():921223. PubMed ID: 35860263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hub ten gene-based risk score system using RNA m
    Yuan B; Liu W; Huo M; Zhang J; Yang Y; Gao T; Yin X; Yang T; Teng X; Huang W; Yu H
    Breast Cancer; 2022 Jul; 29(4):645-658. PubMed ID: 35174450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of m
    Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
    Front Immunol; 2021; 12():782551. PubMed ID: 34975871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of m6A methylation modifications and tumor microenvironment infiltration in thyroid cancer.
    Ji FH; Yang Z; Sun C; Lowe S; Qiu XG
    Clin Transl Oncol; 2023 Jan; 25(1):269-282. PubMed ID: 36163443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating m6A Regulators-Mediated Methylation Modification Models and Tumor Immune Microenvironment Characterization in Caucasian and Chinese Low-Grade Gliomas.
    Liu W; Li C; Wu Y; Xu W; Chen S; Zhang H; Huang H; Zhao S; Wang J
    Front Cell Dev Biol; 2021; 9():725764. PubMed ID: 34900988
    [No Abstract]   [Full Text] [Related]  

  • 10. N6-Methyladenosine Modification Patterns and Tumor Microenvironment Immune Characteristics Associated With Clinical Prognosis Analysis in Stomach Adenocarcinoma.
    Meijing Z; Tianhang L; Biao Y
    Front Cell Dev Biol; 2022; 10():913307. PubMed ID: 35813200
    [No Abstract]   [Full Text] [Related]  

  • 11. m
    Fan Y; Zhou Y; Lou M; Li X; Zhu X; Yuan K
    J Inflamm Res; 2022; 15():1969-1989. PubMed ID: 35356071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m
    Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
    Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular phenotypic linkage between N
    Zhang F; Bi J; Liao J; Zhong W; Yu M; Lu X; Che J; Chen Z; Xu H; Hu S; Liu Y; Guo S
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):6901-6916. PubMed ID: 36826593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive characterization of m6A methylation and its impact on prognosis, genome instability, and tumor microenvironment in hepatocellular carcinoma.
    Yin T; Zhao L; Yao S
    BMC Med Genomics; 2022 Mar; 15(1):53. PubMed ID: 35260168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of m
    Zeng QC; Sun Q; Su WJ; Li JC; Liu YS; Zhang K; Yang LQ
    Sci Rep; 2022 Nov; 12(1):20684. PubMed ID: 36450735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. m6A Regulator-Associated Modification Patterns and Immune Infiltration of the Tumor Microenvironment in Hepatocarcinoma.
    Li J; Wang W; Zhou Y; Liu L; Zhang G; Guan K; Cui X; Liu X; Huang M; Cui G; Sun R
    Front Cell Dev Biol; 2021; 9():687756. PubMed ID: 34277630
    [No Abstract]   [Full Text] [Related]  

  • 17. RNA m
    Zhang Q; Sun X; Sun J; Lu J; Gao X; Shen K; Qin X
    Front Immunol; 2022; 13():905057. PubMed ID: 36389669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in hepatocellular carcinoma.
    Huang X; Qiu Z; Li L; Chen B; Huang P
    Aging (Albany NY); 2021 Aug; 13(16):20698-20715. PubMed ID: 34461607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel m5C/m6A-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Ma Y; Yang J; Ji T; Wen F
    Front Genet; 2022; 13():990623. PubMed ID: 36246622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of a risk prediction model using m6A RNA methylation regulators in prostate cancer: comprehensive bioinformatic analysis and histological validation.
    Quan Y; Zhang X; Ping H
    Cancer Cell Int; 2022 Jan; 22(1):33. PubMed ID: 35045837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.